Licensing
Physiomics plc has signed a license agreement with Eli Lilly under which the Oxford-based company will develop a customised version of its ModelPlayer for in silico simulations of anti-cancer drugs.
ModelPlayer, a computational systems biology application, creates simulations of cell behaviour, enabling drug interactions to be modelled in silico.
Christophe Chassagnole, chief operating officer of Physiomics, said, “This is an important commercial and technical milestone for Physiomics as this is the first time that we have out-licensed our technology.
Receive the Funding Newswire each Tuesday, our Policy Bulletin each Thursday, and news about bridging Europe’s east-west innovation gap twice a month in The Widening. 
A unique international forum for public research organisations and companies to connect their external engagement with strategic interests around their R&D system.